Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources. Economic evidence could support policy decisions to fund expensive interventions. The current analysis evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Xuezhi, Shen, Aizong, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287729/
https://www.ncbi.nlm.nih.gov/pubmed/34290602
http://dx.doi.org/10.3389/fphar.2021.573852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287729/
https://www.ncbi.nlm.nih.gov/pubmed/34290602
http://dx.doi.org/10.3389/fphar.2021.573852

Ejemplares similares